Responses to Backward Walking Training Post-Stroke (BRAVE)
Brain and Behavioral Responses to Backward Walking Training Post-Stroke
Approximately 15,000 Veterans are hospitalized for stroke each year with new cases costing an estimated $111 million for acute inpatient, $75 million for post-acute inpatient, and $88 million for follow-up care over 6 months post-stroke. The investigators have previously established the effectiveness of a backward walking training program to improve gait and balance in post-stroke Veterans. To best serve Veterans in this era of personalized medicine, there is a current need to determine the appropriate training dose as well as which post-stroke Veterans would most benefit. This study addresses both needs as it will 1) test responses to two different doses (18 vs. 27 sessions) of backward walking training and 2) assess brain activity, measured by magnetic resonance imaging, before and after training intervention to determine its ability to predict rehabilitation response as well as brain mechanisms of behavioral change.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This prospective, single-blind, randomized controlled trial will enroll individuals between 2- and 4-months post-stroke and is designed to address the study's three Specific Aims (See Figure below). The study will be approved by an ethics review board and all participants will provide written informed consent. Baseline pre-intervention assessment (Assessment A) will consist of clinical gait and balance assessments and resting state Functional Connectivity MRI and functional MRI. Brain imaging at Assessment A will test the hypotheses that rs-FC and fMRI can predict BWTraining intervention response (Specific Aim 2). Following Assessment A, participants will be randomized to receive 1) 18 sessions or 2) 27-sessions of BWTraining 3x/week for six or nine weeks respectively. Participants in the 18-session group will wait 3 weeks following randomization to begin training such that Assessment B will take place at approximately the same time post-stroke for all participants. This will assure that all participants have had the same duration of time post-stroke after study enrollment to experience spontaneous recovery. Gait and balance measures at Assessment B will be compared to Assessment A to test Specific Aim #1. MRI brain measurements at Assessment B will be compared to those at Assessment A to test the hypotheses of exploratory Aim #3. Assessment C, at six weeks post-intervention will evaluate short-term and Assessment D, at 6-months post-intervention will evaluate long-term retention gains in gait and balance. The investigators will recruit 54 individuals post-stroke to allow up to a 10% attrition rate and still provide a sufficient participant pool (n=48) to address the Specific Aims.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608-1135
- North Florida/South Georgia Veterans Health System, Gainesville, FL
-
Jacksonville, Florida, United States, 32216
- Brooks Rehabilitation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Berg Balance Scale < 45
- Self-selected 10 meter gait speed < 0.8 meters/second (m/s)
- Diagnosis of unilateral stroke
- > 2 months < 4 months post-stroke
- Able to ambulate at least 10 feet with maximum 1 person assist
- Medically stable
Exclusion Criteria:
-
Presence of neurological condition other than stroke
-
Serious cardiac conditions (hospitalization for myocardial infarction or heart surgery within 3 months, history of congestive heart failure, documented serious and unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living)
- Anyone meeting New York Heart Association criteria for Class 3 or Class 4 heart disease will be excluded
-
Severe arthritis or orthopedic problems that limit passive ranges of motion of lower extremity (knee flexion contracture of -10 degrees, knee flexion ROM < 90 degrees, hip flexion contracture > 25 degrees, and ankle plantar flexion contracture > 15 degrees)
-
Severe hypertension with systolic greater than 200 millimeter of mercury (mmHg) and diastolic greater than 110 millimeter of mercury (mmHg) at rest
-
Pain upon ambulation
-
Receiving physical therapy services for mobility and/or gait
-
Living in a skilled nursing facility
-
Any magnetic resonance imaging (MRI) contraindication, including but not limited to the presence of metal, magnetic resonance (MR) sensitive implanted medical devices, or claustrophobia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 27 session group
Participants in this arm will receive 27 sessions of backward walking training. |
Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground. Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground. |
|
Active Comparator: 18 session group
Participants in this arm will receive 18 sessions of backward walking training. |
Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground. Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the time to complete the 10 Meter walk Test
Time Frame: Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
Gait speed will be measured with the 10-Meter Walk Test. Individuals will be given a 3 meter warm-up distance for walking, preceding the 10 meter distance and 3 meters beyond the 10 meters to continue walking. The time that it takes to traverse the 10 meters at the subject's usual pace will be recorded. |
Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
|
Change in the time to complete the Three-Meter Backward Walk Test
Time Frame: Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
Backward (BW) Speed will be assessed with the 3-Meter Backward Walk test (3MBWT). The test consists of a 1 meter warm-up distance, a timed 3 meter distance, followed by an additional 1 meter to continue walking. An average of two trials will be recorded. |
Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
|
Change in the Functional Gait Assessment
Time Frame: Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
A 10-item clinical gait and balance test of dynamic activities. Reported scores range from 0 to 30 with a larger number representing a better score. |
Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
|
Change in the Activity-Specific Balance Confidence Scale
Time Frame: Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
This 16-item self-report measure is used to assess perceived efficacy (self-reported confidence) in maintaining balance while performing a number of activities common in community-dwelling older adults. This scale is reported as an average of the 16 items from 0% to 100% with a larger number representing a better score. |
Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
|
Change in the Berg Balance Scale
Time Frame: Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
This tool consists of 14 items that assesses static and dynamic standing balance, ability to sit, stand up and transfer. The range of this scale is 0-56 with a larger number representing a better score. |
Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the time to complete the 10 Meter walk Test
Time Frame: Change from baseline through study completion, an average of 7 months.
|
Gait speed will be measured with the 10-Meter Walk Test. Individuals will be given a 3 meter warm-up distance for walking, preceding the 10 meter distance and 3 meters beyond the 10 meters to continue walking. The time that it takes to traverse the 10 meters at the subject's usual pace will be recorded. |
Change from baseline through study completion, an average of 7 months.
|
|
Change in the time to complete the Three-Meter Backward Walk Test
Time Frame: Change from baseline through study completion, an average of 7 months.
|
BW Speed will be assessed with the 3-Meter Backward Walk test (3MBWT). The test consists of a 1 meter warm-up distance, a timed 3 meter distance, followed by an additional 1 meter to continue walking. An average of two trials will be recorded. |
Change from baseline through study completion, an average of 7 months.
|
|
Change in the Functional Gait Assessment
Time Frame: Change from baseline through study completion, an average of 7 months.
|
A 10-item clinical gait and balance test of dynamic activities. Reported scores range from 0 to 30 with a larger number representing a better score. |
Change from baseline through study completion, an average of 7 months.
|
|
Change in the Activity-Specific Balance Confidence Scale
Time Frame: Change from baseline through study completion, an average of 7 months.
|
This 16-item self-report measure is used to assess perceived efficacy (self-reported confidence) in maintaining balance while performing a number of activities common in community-dwelling older adults. This scale is reported as an average of the 16 items from 0% to 100% with a larger number representing a better score. |
Change from baseline through study completion, an average of 7 months.
|
|
Change in the Berg Balance Scale
Time Frame: Change from baseline through study completion, an average of 7 months.
|
This tool consists of 14 items that assesses static and dynamic standing balance, ability to sit, stand up and transfer. The range of this scale is 0-56 with a larger number representing a better score. |
Change from baseline through study completion, an average of 7 months.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dorian Kay Rose, PhD MS BS, North Florida/South Georgia Veterans Health System, Gainesville, FL
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- B3542-R
- 5I01RX003542-05 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.